S-1: Allurion Technologies Files S-1 for Potential Resale of Common Stock Upon Conversion of Convertible Notes

Sentiment:

S-1 Filing


Allurion Technologies has filed an S-1 registration statement for the potential resale of up to 30,191,900 shares of common stock upon conversion of convertible notes held by a selling securityholder.

Summary

  • Allurion Technologies has filed an S-1 registration statement related to the potential resale of up to 30,191,900 shares of its common stock.
  • These shares are issuable upon the conversion of convertible senior secured notes held by a selling securityholder.
  • The notes were issued in a private placement under a Note Purchase Agreement dated April 14, 2024, and amended on April 16, 2024.
  • Allurion will not receive any proceeds from the sale of these shares by the selling securityholder.
  • The selling securityholder may resell the shares through public or private transactions at prevailing market prices or negotiated prices.
  • The registration of these shares does not guarantee that the selling securityholder will offer or sell any of them.
  • The last quoted sale price for Allurion's common stock on May 30, 2024, was $1.51 per share.
  • Sales of a substantial number of shares could reduce the market price of Allurion's common stock.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document is a standard filing related to a potential future sale of shares. It contains both positive (potential for capital) and negative (potential for dilution) aspects.

Negatives

  • Sales of a substantial number of shares of common stock in the public market, including the resale of the shares of common stock held by the selling securityholder pursuant to this prospectus, could occur at any time.
  • These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock and make it more difficult for you to sell your stockholdings at times and prices that you determine are appropriate.

Risks

  • Sales of a substantial number of shares of common stock in the public market, including the resale of the shares of common stock held by the selling securityholder pursuant to this prospectus, could occur at any time.
  • These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock and make it more difficult for you to sell your stockholdings at times and prices that you determine are appropriate.
  • The adverse market and price pressures resulting from an offering pursuant to the registration statement may continue for an extended period of time.

Future Outlook

The selling securityholder will continue to offer the securities covered by this prospectus for a significant period of time, the precise duration of which cannot be predicted.

Industry Context

The announcement reflects ongoing financial activities common in publicly traded companies, particularly those that have recently undergone a business combination and are managing their capital structure.

Stakeholder Impact

  • Potential dilution for existing shareholders.
  • Opportunity for the selling securityholder to realize value from their investment.

Next Steps

  • The selling securityholder may offer or sell the securities.
  • The company may need to seek stockholder approval for the conversion of the notes.

Key Dates

DateDescription
2021-03-01Date of original 2021 Term Loan.
2023-02-09Date of Original RIFA and Existing Business Combination Agreement.
2023-08-01Closing Date of the Business Combination.
2023-12-18Date of Chardan Purchase Agreement.
2023-12-29Date of Amendment No. 1 to the Credit Agreement and Guaranty.
2024-04-14Date of Original RTW Note Purchase Agreement and RIFA Amendment.
2024-04-16Date of First Amendment to Note Purchase Agreement and Termination of Fortress Credit Agreement.
2024-05-30Last quoted sale price for Allurion's common stock as reported on the NYSE was $1.51 per share.

Keywords

common stock, convertible notes, resale, registration statement, Allurion Technologies, securities

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.